Summary
Scientists develop a groundbreaking urine test that detects “zombie” cell proteins, enabling early detection of lung cancer and potentially improving patient outcomes and prognosis.
New Urine Test for Early Detection of Lung Cancer
Scientists have developed a groundbreaking urine test that can detect the early signs of lung cancer. This test, the first of its kind, identifies “zombie” cells that can pave the way for cancer to develop. These cells, known as senescent cells, are alive but cannot grow or divide, causing tissue damage and potentially leading to cancer.
The test was created by researchers at the University of Cambridge and is funded by Cancer Research UK. It works by detecting proteins released by these “zombie” cells in urine. The researchers believe that early detection through this simple urine test could lead to earlier treatment interventions, significantly improving patient outcomes and prognosis.
Lung cancer is the leading cause of cancer deaths worldwide, with about 1.8 million deaths each year. Early detection is crucial because lung cancer often has no noticeable symptoms until it has spread through the lungs or to other parts of the body.
The researchers, led by Professor Ljiljana Fruk and Dr. Daniel Munoz Espin, designed the test to detect peptide-cleaving proteins, which are found at higher levels in the presence of “zombie” cells. These proteins are associated with the early stages of cancer and can be detected in urine, making the test non-invasive and easy to use.
The development of this urine test is a significant step forward in the fight against lung cancer. It offers hope for early detection and better treatment outcomes, especially for vulnerable populations and those recovering from lung cancer surgery. The researchers aim to develop this test further and potentially apply it to other types of cancer as well.
